Clofarabine: emerging role in leukemias

Bibliography

• Kantarjian HM, Jeha S, Gandhi V, et al. Clofarabine: past, present, and future. Leukemia Lymphoma 2007;48(10):1922-30
   PubMed Web of Science ®Google Scholar
• Carson DA, Wasson DB, Esparza LM, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine. Proc Natl Acad Sci USA 1992;89(7):2970-4
   PubMed Web of Science ®Google Scholar
• Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nature Rev 2006;5(10):855-63
   Web of Science ®Google Scholar
• Eriksson S, Arner E, Spasokoukotskaja T, et al. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv Enzyme Regul 1994;34:13-25
   PubMedGoogle Scholar
• Faderl S, Gandhi V, Kantarjian HM. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Curr Opin Hematol 2008;15(2):101-7
   PubMed Web of Science ®Google Scholar
• Chen LS, Plunkett W, Gandhi V. Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues. Leuk Res 2008;32(10):1573-81
   PubMed Web of Science ®Google Scholar
• Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000;96(10):3537-43
   PubMed Web of Science ®Google Scholar
• Waud WR, Schmid SM, Montgomery JA, Secrist JA 3rd. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids 2000;19(1-2):447-60
   PubMed Web of Science ®Google Scholar
• Lotfi K, Mansson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999;5(9):2438-44
   PubMed Web of Science ®Google Scholar
• Lindemalm S, Liliemark J, Gruber A, et al. Comparison of cytotoxicity of 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. Haematologica 2003;88(3):324-32
   PubMed Web of Science ®Google Scholar
• Takahashi T, Kanazawa J, Akinaga S, et al. Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol 1999;43(3):233-40
   PubMed Web of Science ®Google Scholar
• Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 2003;9(17):6335-42
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21(6):1167-73
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102(7):2379-86
   PubMed Web of Science ®Google Scholar
• Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103(3):784-9
   PubMed Web of Science ®Google Scholar
• Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006;24(12):1917-23
   PubMed Web of Science ®Google Scholar
• Kearns P, Michel G, Nelken B, et al. A European phase ii study (BIOV-111) of clofarabine (Evoltra(R)) in refractory and relapsed childhood acute lymphoblastic leukemia: final results. ASH Annual Meeting Abstracts 2007;110(11):11
   Google Scholar
• Cooper T, Ayres M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 2005;55(4):361-8
   PubMed Web of Science ®Google Scholar
• Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105(3):940-7
   PubMed Web of Science ®Google Scholar
• Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006;108(1):45-51
   PubMed Web of Science ®Google Scholar
• Faderl S, Ferrajoli A, Wierda W, et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 2008;113(8):2090-6
   PubMed Web of Science ®Google Scholar
• Burnett AK, Kell WJ, Hills RK, et al. The feasibility of combining daunorubicin, clofarabine and gemtuzumab ozogamicin is feasible and effective. A Pilot Study. ASH Annual Meeting Abstracts 2006;108(11):1950
   Google Scholar
• Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112(5):1638-45
   PubMed Web of Science ®Google Scholar
• Burnett AK, Baccarani M, Johnson P, et al. A phase II study (biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable. ASH Annual Meeting Abstracts 2006;108(11):425
   Google Scholar
• Erba HP, Kantarjian H, Claxton DF, et al. Phase II study of single agent clofarabine in previously untreated older adult patients with Acute Myelogenous Leukemia (AML) unlikely to benefit from standard induction chemotherapy. ASH Annual Meeting Abstracts 2008;112(11):558
   Google Scholar
• Faderl S, Garcia-Manero G, Ravandi F, et al. Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS). ASH Annual Meeting Abstracts 2008;112(11):222
   Google Scholar